{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:35:27Z","timestamp":1771014927236,"version":"3.50.1"},"reference-count":68,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T00:00:00Z","timestamp":1745712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001637","name":"Trinity College Dublin","doi-asserted-by":"publisher","award":["Panoz PhD Scholarship from the School of Pharmacy"],"award-info":[{"award-number":["Panoz PhD Scholarship from the School of Pharmacy"]}],"id":[{"id":"10.13039\/501100001637","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To identify, evaluate and summarize all published literature that investigated manipulations to pharmaceutical dosage forms of psychotropic medications that could be used for the purposes of tapering.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature review was carried out of the available published literature on manipulations performed to psychotropic medications to obtain a decreased dose of the active pharmaceutical ingredient. All studies that involved the manipulation of pharmaceutical dosage forms of antidepressants or benzodiazepine receptor agonists and subsequent pharmaceutical analysis of active pharmaceutical ingredient content were eligible for inclusion. The electronic databases searched were: MEDLINE, Web of Science, EMBASE, PsycINFO and CINAHL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixteen studies met inclusion criteria. The manipulation methods carried out in the identified studies involved tablet splitting (4 studies), formulation of liquid suspensions (8 studies) and diluting existing marketed liquid formulations (4 studies). Ten of the included studies reported a mean target dose recovery within the 95\u2013105% range after the manipulation was performed. All studies in which a dilution was performed to an oral liquid formulation (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094) reported results within this percentage recovery range. None of the included studies investigated the accuracy of manipulations across the full dose range of a tapering schedule.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This review identified a limited amount of published research on the accuracy of different methods of manipulating psychotropic medications. Diluting liquid formulations to achieve lower doses merits further investigation. Further research comparing different manipulation methods is also required to determine the best approach for tapering to lower doses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70082","type":"journal-article","created":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T23:44:27Z","timestamp":1745797467000},"page":"1899-1913","source":"Crossref","is-referenced-by-count":3,"title":["A systematic review of manipulations to pharmaceutical dosage forms used in psychotropic tapering plans"],"prefix":"10.1002","volume":"91","author":[{"given":"Denis","family":"O'Brien","sequence":"first","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences Trinity College Dublin  Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Marie","family":"Healy","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences Trinity College Dublin  Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Harkin","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences Trinity College Dublin  Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8778-0112","authenticated-orcid":false,"given":"Cathal","family":"Cadogan","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences Trinity College Dublin  Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,4,27]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)02143\u20107"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215\u20100366(21)00292\u20103"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215\u20100366(19)30331\u20101"},{"key":"e_1_2_11_5_1","unstructured":"NHS Business Services News.NHS releases mental health medicines statistics for 2020\u201321 in England.2022. Accessed October 11 2024.https:\/\/media.nhsbsa.nhs.uk\/news\/nhs-releases-mental-health-medicines-statistics-for-2020-21-in-england"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwp142"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2018.08.027"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2015.06.052"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2015.01.055"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/0004867419898761"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14475"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1611832"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2017.05.048"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.v03n0105"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125321991274"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/0004867420979353"},{"key":"e_1_2_11_17_1","unstructured":"National Institute for Health and Care Excellence.Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults.2022. Accessed October 11 2024.https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ng10141"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j3927"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.141.7.848"},{"issue":"2","key":"e_1_2_11_20_1","first-page":"237","article-title":"Antidepressant withdrawal phenomena","volume":"19","author":"Dilsaver SC","year":"1984","journal-title":"Biol Psychiatry"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000371865"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125320921694"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1192\/bja.2021.62"},{"key":"e_1_2_11_24_1","unstructured":"National Institute for Health and Care Excellence.Depression in adults: recognition and management. Accessed October 11 2024.https:\/\/www.nice.org.uk\/guidance\/cg90"},{"issue":"4","key":"e_1_2_11_25_1","article-title":"Approaches for discontinuation versus continuation of long\u2010term antidepressant use for depressive and anxiety disorders in adults","volume":"4","author":"Van Leeuwen E","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215\u20100366(19)30032\u2010X"},{"key":"e_1_2_11_27_1","volume-title":"The Maudsley deprescribing guidelines: antidepressants, benzodiazepines, Gabapentinoids and Z\u2010drugs","author":"Horowitz MA","year":"2024"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.5.826"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2336"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.22598"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/10783903231185353"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125320981174"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp21X716309"},{"key":"e_1_2_11_34_1","article-title":"The PRISMA 2020 Statement: an updated guideline for reporting systematic reviews","volume":"2021","author":"Page MJ","journal-title":"BMJ"},{"issue":"2","key":"e_1_2_11_35_1","first-page":"S223","article-title":"The concise guide to PHARMACOLOGY 2023\/24: nuclear hormone receptors","volume":"180","author":"Alexander SPH","year":"2023","journal-title":"Br J Pharmacol"},{"issue":"1","key":"e_1_2_11_36_1","first-page":"81","article-title":"Stability of venlafaxine immediate\u2010release suspensions","volume":"15","author":"Donnelly RF","year":"2011","journal-title":"Int J Pharm Compd."},{"issue":"4","key":"e_1_2_11_37_1","first-page":"344","article-title":"Stability of midazolam in syrspend SF and syrspend SF cherry","volume":"17","author":"Geiger CM","year":"2013","journal-title":"Int J Pharm Compd."},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2015.21.1.76"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2009.15.3.253"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551\u20106776\u201010.1.36"},{"issue":"3","key":"e_1_2_11_41_1","first-page":"143","article-title":"The stability of extemporaneously prepared solutions of fluoxetine HCl","volume":"4","author":"Marshall TM","year":"1994","journal-title":"Pharm Sci Commun"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/33.5.450"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573412911309040004"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/51.10.1342"},{"issue":"4","key":"e_1_2_11_45_1","first-page":"185","article-title":"Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa\/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend SF PH4 oral suspensions","volume":"17","author":"Polonini HC","year":"2016","journal-title":"Pharm"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm\u20102016\u2010000903"},{"issue":"5","key":"e_1_2_11_47_1","first-page":"426","article-title":"Stability of allopurinol, amitriptyline hydrochloride, carbamazepine, domperidone, isoniazid, ketoconazole, lisinopril, naproxen, paracetamol (acetaminophen), and sertraline hydrochloride in SyrSpend SF PH4 Oral suspensions","volume":"20","author":"Polonini HC","year":"2016","journal-title":"Int J Pharm Compd"},{"issue":"6","key":"e_1_2_11_48_1","first-page":"440","article-title":"Stability of clonazepam suspension in HSC vehicle","volume":"1","author":"Roy JJ","year":"1997","journal-title":"Int J Pharm Compd"},{"issue":"1","key":"e_1_2_11_49_1","first-page":"17","article-title":"Stability of parenteral midazolam in an oral formulation","volume":"44","author":"Walker SE","year":"1997","journal-title":"Anesth Prog"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.5731\/pdajpst.2012.00791"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2011.12.009"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbab017"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2020.000080"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115303"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2021.10.001"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0282988"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102648.2010.05477.x"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.3399\/BJGPO.2022.0001"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2013.12.014"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096\u2010023\u201001602\u2010z"},{"key":"e_1_2_11_61_1","first-page":"70","article-title":"Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review","author":"Brandt J","year":"2024","journal-title":"eClinicalMedicine"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102024\u2010088266"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40900\u2010016\u20100026\u2010y"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/hex.13962"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/hex.13392"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/hex.13966"},{"key":"e_1_2_11_67_1","first-page":"1","article-title":"Strength and stability testing for compounded preparations","author":"Allen LV","year":"2014","journal-title":"US Pharmacop"},{"key":"e_1_2_11_68_1","volume-title":"ICH Q6A specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances \u2010 scientific guideline","year":"2000"},{"key":"e_1_2_11_69_1","unstructured":"British Pharmacopoeia.Substances for pharmaceutical use.2025. Accessed October 11 2024.https:\/\/www.pharmacopoeia.com\/bp-2025\/monographs\/substances-for-pharmaceutical-use.html?date=2025-04-01"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T03:49:26Z","timestamp":1764560966000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,27]]},"references-count":68,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1002\/bcp.70082"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70082","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,27]]}}}